Inflammation in obesity-related HFpEF: the STEP-HFpEF programme

Back

ESC Premium Access

Inflammation in obesity-related HFpEF: the STEP-HFpEF programme

Session: Clinical trial updates on the GLP-1 receptor agonist, semaglutide

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Professor S. Verma (Toronto, CA)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)

31 presentations

2 followers

7 more presentations in this session

Atrial fibrillation and efficacy of semaglutide 2.4 mg in obesity-related HFpEF: A Patient Level Pooled analysis of STEP-HFpEF and STEP-HFpEF DM trials

Speaker: Doctor M. Kosiborod (Kansas City, US)

Access

Slides

Video

STEP-HFpEF Program Echocardiography Substudy

Speaker: Professor S. Solomon (Boston, US)

Access

Slides

Video

Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease

Speaker: Doctor R. Pratley (Orlando, US)

Access

Slides

Video

Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials

Speaker: Doctor M. Kosiborod (Kansas City, US)

Access

Slides

Video

Semaglutide and cardiovascular outcomes in females with overweight and obesity: A prespecified analysis of the SELECT trial

Speaker: Professor S. Verma (Toronto, CA)

Access

Slides

Video

Access the full session

Clinical trial updates on the GLP-1 receptor agonist, semaglutide

Speakers: Professor S. Verma, Doctor M. Kosiborod, Professor S. Solomon, Doctor R. Pratley, Doctor M. Kosiborod...

Access

Video

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources